EGS Beteiligungen, the investment arm of the Ernst Göhner Foundation, has exercised its right to convert Siegfried convertible bonds issued in December 2020 with a coupon of 1.15% and a nominal value of CHF40m (US$47m) into shares of global life sciences company, Siegfried Holding.
The Swiss investor receives 48,054 shares, increasing its stake in Siegfried from 6.2% to about 7.2% registered shares. Shares will be delivered from Siegfried’s treasury shares without issuance of new shares.
“The increase in the shareholding of EGS Beteiligungen through this conversion reflects the confidence of our largest shareholder in our business model and strategy,” said Siegfried’s CEO Marcel Imwinkelried.
EGS Beteiligungen participated in the financing of Siegfried’s acquisition of two pharmaceutical production sites in Spain through two hybrid convertible bonds issued by Siegfried.